Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Overview

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an autoimmune disorder that causes progressive weakness and sensory loss in the arms and legs. It is the chronic counterpart of Guillain-Barré syndrome and is characterized by immune-mediated demyelination of peripheral nerves. CIDP represents the most common chronic autoimmune neuropathy worldwide.

Epidemiology

• Prevalence: 1-2 per 100,000 population
• Age of onset: Can occur at any age, most commonly in adults aged 40-60
• Gender distribution: Slight male predominance (M:F = 1.5:1)
• Course: Variable—some patients have monophasic illness, others have relapsing-remitting or progressive pattern

Pathophysiology

Immune-Mediated Demyelination

CIDP is characterized by immune-mediated damage to the myelin sheath of peripheral nerves. The exact trigger is unknown, but the disease involves both cellular and humoral immune responses:

T-cell mediated damage: Autoreactive T-cells target myelin proteins

Macrophage-mediated demyelination: Activated macrophages attack myelin

Antibody-mediated injury: Autoantibodies target myelin proteins and lipids

Associated Conditions

In some cases, CIDP may be associated with other conditions:

• Diabetes mellitus
• HIV infection
• Monoclonal gammopathy (MGUS)
• Lymphoma
• Systemic lupus erythematosus

Clinical Features

Symptoms

...

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Overview

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an autoimmune disorder that causes progressive weakness and sensory loss in the arms and legs. It is the chronic counterpart of Guillain-Barré syndrome and is characterized by immune-mediated demyelination of peripheral nerves. CIDP represents the most common chronic autoimmune neuropathy worldwide.

Epidemiology

• Prevalence: 1-2 per 100,000 population
• Age of onset: Can occur at any age, most commonly in adults aged 40-60
• Gender distribution: Slight male predominance (M:F = 1.5:1)
• Course: Variable—some patients have monophasic illness, others have relapsing-remitting or progressive pattern

Pathophysiology

Immune-Mediated Demyelination

CIDP is characterized by immune-mediated damage to the myelin sheath of peripheral nerves. The exact trigger is unknown, but the disease involves both cellular and humoral immune responses:

T-cell mediated damage: Autoreactive T-cells target myelin proteins

Macrophage-mediated demyelination: Activated macrophages attack myelin

Antibody-mediated injury: Autoantibodies target myelin proteins and lipids

Associated Conditions

In some cases, CIDP may be associated with other conditions:

• Diabetes mellitus
• HIV infection
• Monoclonal gammopathy (MGUS)
• Lymphoma
• Systemic lupus erythematosus

Clinical Features

Symptoms

• Progressive weakness: Arms and legs, typically symmetric
• Sensory loss: Numbness, particularly in hands and feet
• Loss of deep tendon reflexes: Diminished or absent
• Difficulty walking: Gait disturbance
• Fatigue: Generalized fatigue
• Pain: Particularly in back and legs
• Balance problems: Due to sensory and motor impairment

Clinical Variants

• Typical CIDP: Classic presentation with symmetric proximal and distal weakness
• Atypical CIDP: Includes pure sensory, pure motor, or focal variants
• MADSAM: Multifocal acquired demyelinating sensory and motor neuropathy (Lewis-Sumner syndrome)

Diagnosis

Clinical Criteria

Diagnosis is based on a combination of:

• Clinical presentation: Progressive,relatively symmetric motor and sensory neuropathy
• Nerve conduction studies: Showing demyelination (temporal dispersion, conduction block, slowed velocities)
• Cerebrospinal fluid analysis: Elevated protein with normal cell count (albuminocytologic dissociation)
• Nerve biopsy: May be performed in atypical cases

Diagnostic Workup

Neurological examination: Assess strength, sensation, reflexes

Nerve conduction studies/EMG: Confirm demyelination

Lumbar puncture: CSF protein elevation

Blood tests: Rule out associated conditions

Nerve biopsy: In selected cases

Differential Diagnosis

CIDP must be distinguished from:

• Guillain-Barré syndrome (acute inflammatory demyelinating polyradiculoneuropathy)
• Multifocal motor neuropathy
• Charcot-Marie-Tooth Disease (hereditary)
• Diabetic neuropathy
• Vasculitic neuropathy

Treatment

First-Line Therapies

Corticosteroids (prednisone): Effective but significant long-term side effects

Intravenous immunoglobulin (IVIG): Often preferred due to rapid onset and favorable side effect profile

Plasma exchange (plasmapheresis): Used in severe or refractory cases

Second-Line and Adjunctive Therapies

• Immunosuppressive agents: Azathioprine, mycophenolate, cyclophosphamide, rituximab
• Subcutaneous immunoglobulin: Alternative for maintenance therapy

Treatment Response

• IVIG: Response in 50-70% of patients; effects typically last weeks to months
• Corticosteroids: Effective in many patients; require maintenance therapy
• Plasma exchange: Particularly useful for acute exacerbations

Prognosis

The prognosis for CIDP varies significantly among patients:

• Monophasic course: Some individuals experience complete recovery
• Relapsing-remitting pattern: Periodic treatments needed
• Progressive course: Gradual worsening despite treatment

Factors associated with better outcomes:

• Early diagnosis and treatment
• Fewer relapses
• Younger age at onset
• Absence of underlying disease

Research Directions

Current research focuses on:

• Biomarkers for treatment response: Identifying predictors of therapeutic benefit
• Underlying autoimmune mechanisms: Understanding the exact pathophysiology
• Novel therapies: Investigating targeted immunosuppressive agents
• Stem cell therapy: Exploring regenerative approaches
• Gene therapy: Potential future treatments

Pathway & Interaction Diagram

Interactive diagram showing cidp's key relationships in the SciDEX knowledge graph (7 connections shown).

See Also

• [Guillain-Barré Syndrome](/diseases/guillain-barre-syndrome)
• [Multiple Sclerosis](/diseases/multiple-sclerosis)
• [Peripheral Neuropathy](/diseases/peripheral-neuropathy)

External Links

• [NINDS CIDP Information](https://www.ninds.nih.gov/health-information/disorders/chronic-inflammatory-demyelinating-polyneuropathy-cidp)
• [Mayo Clinic - CIDP](https://www.mayoclinic.org/diseases-conditions/cidp/symptoms-causes/syc-20351134)
• [Foundation for Peripheral Neuropathy](https://www.foundationforpn.org)
• [GBS/CIDP Foundation International](https://www.gbscidp.org/)

References

Rajabally Y, et al., Chronic inflammatory demyelinating polyneuropathy: a worldwide epidemiology study. Neurology. 2019 (2019)

Van den Bergh PY, et al., Consensus on the treatment of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2020 (2020)

Kline DG, et al., Clinical presentation and diagnosis of chronic inflammatory demyelinating polyneuropathy. Neurosurgery. 2019 (2019)